Understanding Fluidized-Bed Granulation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Understanding Fluidized-Bed Granulation
This study demonstrates the beneficial use of a spatial-filter velocimetry particle-size analyzer during granulation.


Pharmaceutical Technology
Volume 35, Issue 8, pp. 63-67

Results and discussion


Figure 1: Average D50 results obtained with spatial-filter velocimetry (SFV) and laser diffraction (LD) for all design-of-experiments batches. (ALL FIGURES ARE COURTESY OF THE AUTHORS)
Comparison of in-line SFV and off-line LD particle-size measurements. The GSD of the end products measured in-line using SFV was compared with the off-line determined LD granule sizes for all DOE batches. Although SFV and LD are based on different measurement principles (LD assumes spherical particles, whereas SFV does not), similar GSDs were expected. Figure 1 displays the average D50 values measured with SFV (i.e., the average of the last granulation minute, or six data points) and LD for the end granules of all 19 DOE batches. Similar D50 differences between the 19 experiments were obtained by the two particle-sizing techniques. However, D50 sizes measured with LD were always lower than those obtained by SFV. The same observations were made for the D10 and D90 values.


Figure 2a: Differences between average D50 values measured with spatial-filter velocimetry (SFV) and laser diffraction (LD), arranged according to increasing SFV particle size.
The authors believe that this difference in GSD is caused by the LD measurement technique. The quantified particles experience rapid accelerations as the air stream passes through a venturi. The high shear applied during this process and the subsequent collisions with the wall of the apparatus may cause granules to break or crumble. Pressurized air also disperses the granules during the SFV measurements, but the particles pass directly through the measurement zone. No collisions occur because high shear is not applied. The authors' hypothesis was confirmed by the GSD measurement of low-friability spherical granules (i.e., Cellets 100, 200, and 350, Pharmatrans Sanaq Pharmaceuticals) using SFV and LD under software and experimental settings identical to those for the DOE granules. The LD measurements did not systematically underestimate the GSD, in contrast to observations obtained for the breakable granules. An additional explanation for the discrepancy between SFV and LD values might be found in the assumption of a spherical shape during LD measurements.


Figure 2b: Differences between average D50 values measured with spatial-filter velocimetry (SFV) and laser diffraction (LD), arranged according to increasing LD particle size.
Size segregation during fluidization should also be addressed because it influences in-line SFV measurements (23). Inappropriate fluidization can cause a high amount of larger granules to be present in the lower part of the chamber and a high amount of smaller granules to appear in the upper part of the chamber. The SFV probe is placed in the upper part of the chamber, which the largest particles cannot reach under low inlet airflow rates, potentially resulting in an underestimation of granule size. Figures 2a and 2b display the difference between SFV and LD D50 results for the 19 DOE batches, arranged according to increasing SFV end-granule size and LD end-granule size in the x axes, respectively. Because these differences did not increase as a function of increasing end granule size, the authors concluded that no size segregation had occurred.

These primary results suggest that although a systematic difference exists between LD and SFV data, the SFV technique can successfully measure the actual particle-size distribution during granulation.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here